OSI Receives Allowance of U.S. Patent for c-Kit/KDR Compound, OSI-930

OSI Pharmaceuticals has announced that its patent application covering claims for its lead c-Kit/KDR compound, OSI-930, has received notice of allowance by the U.S. Patent and Trademark Office.

The resulting patent will cover the compound, compositions containing the compound, and methods of treating cancers with the compound. The issuance of this patent provides protection of OSI-930 until 2024.